INDICATION & IMPORTANT SAFETY INFORMATION

Indication

FILSUVEZ is indicated for the treatment of
wounds associated with dystrophic and junctional
epidermolysis bullosa (EB) in adult and pediatric
patients 6 months of age and older.

Important Safety Information

Warnings & Precautions

Local hypersensitivity and skin reactions have been
reported in patients treated with FILSUVEZ, including
urticaria and dermatitis. If signs or symptoms of
hypersensitivity occur, discontinue use immediately
and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in
clinical trials was pruritus and pain at the wound
application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for
administration instructions.

To report SUSPECTED ADVERSE REACTIONS,
contact Chiesi USA Inc. at 1-888-661-9260 or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

©2025 Chiesi USA, Inc. All rights reserved.
FILSUVEZ is a registered trademark owned by the
Chiesi Group.
PP-RA-01219 V1.0